Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OncoSil Medical Ltd ( (AU:OSL) ) has shared an update.
OncoSil Medical Ltd has applied for quotation on the ASX of 2,951,918 new fully paid ordinary shares and an equal number of deferred options expiring on 30 June 2027. The new securities, issued on 17 March 2026 and linked to a previously announced transaction, will expand the company’s tradable capital base and may influence liquidity and investor positioning in the stock.
The application under Appendix 2A formalises the transition of these securities to quoted status on the Australian Securities Exchange under ticker OSL. This step reflects ongoing capital management activities that could support OncoSil Medical’s operational and strategic initiatives in the medical technology and oncology markets.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an ASX-listed medical company focused on developing and commercialising oncology-related products. The company operates in the healthcare and medical technology sector, targeting cancer treatment markets through specialised therapeutic solutions.
Average Trading Volume: 61,650
Technical Sentiment Signal: Sell
Current Market Cap: A$13.22M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.